首页 中华核医学与分子影像杂志 2025年45卷02期 靶向整合素的放射性药物在肿瘤诊疗中的研究进展
中华核医学与分子影像杂志
期刊首页
过刊列表
高级检索
稿件发表
• 综述 •
ENGLISH ABSTRACT
靶向整合素的放射性药物在肿瘤诊疗中的研究进展
杨广杰
霍力 
作者及单位信息
·
DOI： 10.3760/cma.j.cn321828-20240204-00053
Research progress of integrin-targeted radiopharmaceuticals in tumor diagnosis and treatment
Yang Guangjie
Huo Li
Authors Info & Affiliations
Yang Guangjie
Department of Nuclear Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences; Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing 100730, China
Huo Li
Department of Nuclear Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences; Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing 100730, China
·
DOI： 10.3760/cma.j.cn321828-20240204-00053
0
0
0
0
0
0
扫描转手机阅读
下载中华医学期刊APP阅读更流畅 体验更丰富
PDF下载
APP内阅读
摘要
整合素是一类跨膜糖蛋白，在肿瘤新生血管内皮细胞及多种肿瘤细胞中高表达，而在正常组织低表达或不表达。靶向整合素的放射性诊断或治疗性药物可以无创、在体显示肿瘤特性、评估血管新生情况以及对肿瘤进行放射靶向治疗等，具有较大的临床应用价值。该文就靶向整合素的放射性药物在肿瘤诊断和治疗中的研究进展进行综述。
肿瘤;放射性药物;整合素类;发展趋势
ABSTRACT
Integrin is a kind of transmembrane glycoprotein, which is highly expressed in tumor neovascular endothelial cells and various tumor cells, but lowly or negatively expressed in normal tissues. Integrin-targeted diagnostic or therapeutic radiopharmaceuticals can non-invasively display tumor characteristics in vivo, evaluate angiogenesis and perform targeted radiotherapy for tumors, which have great clinical application value. This article reviews the research progress of radiopharmaceuticals targeting integrins in tumor diagnosis and treatment.
Neoplasms;Radiopharmaceuticals;Integrins;Trends
Huo Li, Email:
nc.defhcabmupilouh
Copyright by Chinese Medical Association
No content published by the journals of Chinese Medical Association may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journals without permission.
All articles published represent the opinions of the authors, and do not reflect the official policy of the Chinese Medical Association or the Editorial Board, unless this is clearly specified.
引用本文
杨广杰,霍力. 靶向整合素的放射性药物在肿瘤诊疗中的研究进展[J]. 中华核医学与分子影像杂志,2025,45(02)：114-119.
DOI:10.3760/cma.j.cn321828-20240204-00053PERMISSIONS
Request permissions for this article from CCC.
评价本文
*以上评分为匿名评价
本文评分
5分
[累计个]
向我们报错
版权归中华医学会所有。
未经授权，不得转载、摘编本刊文章，不得使用本刊的版式设计。
除非特别声明，本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。
整合素(integrin)是细胞黏附分子家族的重要成员，在肿瘤新生血管内皮细胞及多种肿瘤细胞中高表达，而在正常组织低表达或不表达。整合素由1个α亚基和1个β亚基非共价结合形成异二聚体，目前共发现18种α亚基和8种β亚基，形成24种整合素。不同的整合素亚型在特定的肿瘤类型中表达水平不同，通过对整合素亚型进行核医学显像可以特异性检测肿瘤类型，并且能直观反映整合素的表达水平，进而监测肿瘤生长、指导与整合素相关的治疗方案选择以及评估治疗反应。此外，通过标记不同的治疗性核素(如
177Lu、
225Ac)，可以利用整合素靶向分子实现肿瘤核素治疗。因此，整合素靶向放射性药物的体内显像特性尤为重要。本文主要讨论靶向不同整合素亚型的放射性药物研究现状，以期为整合素相关放射性药物的开发和应用提供参考。
试读结束，您可以通过登录机构账户或个人账户后获取全文阅读权限。
已是订阅账户?
登录
参考文献
[1]
Ludwig BS , Kessler H , Kossatz S ,et al. RGD－binding integrins revisited: how recently discovered functions and novel synthetic ligands (re－)shape an ever－evolving field[J]. Cancers (Basel), 2021,13(7):1711. DOI：
10.3390/cancers13071711
.
[2]
Debordeaux F , Chansel－Debordeaux L , Pinaquy JB ,et al.
What about α
v
β
3
integrins in molecular imaging in oncology？
[J]. Nucl Med Biol, 2018,62－63:31－46. DOI：
10.1016/j.nucmedbio.2018.04.006
.
[3]
Badipa F , Alirezapour B , Yousefnia H . An overview of radiolabeled RGD peptides for theranostic applications[J]. Curr Radiopharm, 2023,16(2):107－122. DOI：
10.2174/1874471016666221207122731
.
[4]
Notni J . RGD Forever！—Past, present, and future of a 3－letter－code in radiopharmacy and life sciences[J]. Pharmaceuticals (Basel), 2022,16(1):56. DOI：
10.3390/ph16010056
.
[5]
Haubner R , Weber WA , Beer AJ ,et al.
Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [
18
F
]
Galacto－RGD
[J]. PLoS Med, 2005,2(3):e70. DOI：
10.1371/journal.pmed.0020070
.
[6]
Liu S , Liu H , Jiang H ,et al.
One－step radiosynthesis of
18
F－AlF－NOTA－RGD
2
for tumor angiogenesis PET imaging
[J]. Eur J Nucl Med Mol Imaging, 2011,38(9):1732－1741. DOI：
10.1007/s00259-011-1847-4
.
[7]
Wan W , Guo N , Pan D ,et al.
First experience of
18
F－Alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination
[J]. J Nucl Med, 2013,54(5):691－698. DOI：
10.2967/jnumed.112.113563
.
[8]
Wu J , Tian J , Zhang Y ,et al.
18
F－AlfatideⅡfor the evaluation of axillary lymph nodes in breast cancer patients: comparison wi
th
18
F－FDG
[J]. Eur J Nucl Med Mol Imaging, 2022,49(8):2869－2876. DOI：
10.1007/s00259-021-05333-z
.
[9]
Lobeek D , Rijpkema M , Terry S ,et al.
Imaging angiogenesis in patients with head and neck squamous cell carcinomas by [
68
Ga
]
Ga－DOTA－E－[c(RGDfK)
]
2
PET/CT
[J]. Eur J Nucl Med Mol Imaging, 2020,47(11):2647－2655. DOI：
10.1007/s00259-020-04766-2
.
[10]
Lang L , Li W , Guo N ,et al.
Comparison study of [
18
F
]
FAl－NOTA－PRGD
2
, [
18
F
]
FPPRGD
2
, and [
68
Ga
]
Ga－NOTA－PRGD
2
for PET imaging of U87MG tumors in mice
[J]. Bioconjug Chem, 2011,22(12):2415－2422. DOI：
10.1021/bc200197h
.
[11]
Zheng K , Liang N , Zhang J ,et al.
68
Ga－NOTA－PRGD
2
PET/CT for integrin imaging in patients with lung cancer
[J]. J Nucl Med, 2015,56(12):1823－1827. DOI：
10.2967/jnumed.115.160648
.
[12]
Carlsen EA , Loft M , Loft A ,et al.
Prospective phase Ⅱ trial of [
68
Ga
]
Ga－NODAGA－E[c(RGDyK)
]
2
PET/CT imaging of integrin α
v
β
3
for prognostication in patients with neuroendocrine neoplasms
[J]. J Nucl Med, 2023,64(2):252－259. DOI：
10.2967/jnumed.122.264383
.
[13]
王俊，付晶晶，唐潇伟，等.
68
Ga－NODAGA－RGD PET/CT预测酪氨酸激酶抑制剂治疗远处转移性分化型甲状腺癌短期疗效的研究
[J]. 中华核医学与分子影像杂志， 2023,43(8):459－464. DOI：
10.3760/cma.j.cn321828-20230428-00114
.
Wang J , Fu JJ , Tang XW ,et al.
Study of
68
Ga－NODAGA－RGD PET/CT in predicting short－term efficacy of tyrosine kinase inhibitor in the treatment of distant metastatic differentiated thyroid cancer
[J]. Chin J Nucl Med Mol Imaging, 2023,43(8):459－464. DOI：
10.3760/cma.j.cn321828-20230428-00114
.
[14]
Lobeek D , Franssen GM , Ma MT ,et al.
In vivo
characterization of 4
68
Ga－labeled multimeric RGD peptides to image α
v
β
3
integrin expression in 2 human tumor xenograft mouse models
[J]. J Nucl Med, 2018,59(8):1296－1301. DOI：
10.2967/jnumed.117.206979
.
[15]
Li ZB , Cai W , Cao Q ,et al.
64
Cu－labeled tetrameric and octameric RGD peptides for small－animal PET of tumor α
v
β
3
integrin expression
[J]. J Nucl Med, 2007,48(7):1162－1171. DOI：
10.2967/jnumed.107.039859
.
[16]
Zhu Z , Miao W , Li Q ,et al.
99
Tc
m
－3PRGD
2
for integrin receptor imaging of lung cancer: a multicenter study
[J]. J Nucl Med, 2012,53(5):716－722. DOI：
10.2967/jnumed.111.098988
.
[17]
Xiao L , Xin J .
Advances in clinical oncology research on
99
Tc
m
－3PRGD
2
SPECT imaging
[J]. Front Oncol, 2022,12:898764. DOI：
10.3389/fonc.2022.898764
.
[18]
Shi J , Fan D , Dong C ,et al.
Anti－tumor effect of integrin targeted
177
Lu－3PRGD
2
and combined therapy with Endostar
[J]. Theranostics, 2014,4(3):256－266. DOI：
10.7150/thno.7781
.
[19]
Gao H , Yang G , Luo C ,et al.
A long－acting radiolabeled RGD analogue Lu－177－AB－3PRGD
2
for targeted radiotherapy of tumor
[J]. J Label Compd Radiopharm, 2019,62:S43－S44.
[20]
Wen X , Zeng X , Liu J ,et al.
Synergism of
64
Cu－labeled RGD with anti－PD－L1 immunotherapy for the long－acting antitumor effect
[J]. Bioconjug Chem, 2022,33(11):2170－2179. DOI：
10.1021/acs.bioconjchem.2c00408
.
[21]
Chen H , Zhao L , Fu K ,et al.
Integrin α
v
β
3
－targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti－tumor efficacy
[J]. Theranostics, 2019,9(25):7948－7960. DOI：
10.7150/thno.39203
.
[22]
Zhao L , Chen H , Guo Z ,et al.
Targeted radionuclide therapy in patient－derived xenografts using
177
Lu－EB－RGD
[J]. Mol Cancer Ther, 2020,19(10):2034－2043. DOI：
10.1158/1535-7163.MCT-19-1098
.
[23]
王国昌，徐鹏飞，张静静，等．伊文思蓝改构放射性药物在诊疗一体化中的应用进展[J]. 中华核医学与分子影像杂志， 2024,44(1):35－40. DOI：
10.3760/cma.j.cn321828-20221107-00335
.
Wang GC , Xu PF , Zhang JJ ,et al. Application progress of Evans blue modified radiopharmaceuticals for theranostics[J]. Chin J Nucl Med Mol Imaging, 2024,44(1):35－40. DOI：
10.3760/cma.j.cn321828-20221107-00335
.
[24]
中华医学会核医学分会，中国生物物理学会分子影像学分会．整合素RGD受体显像临床应用专家共识(2022版)[J]. 协和医学杂志， 2022,13(2)：227－234. DOI：
10.12290/xhyxzz.2022-0089
.
Chinese Society of Nuclear Medicine,Chinese Society of Molecular Imaging in Chinese Biophysical Society. Expert consensus on clinical application of integrin RGD receptor imaging (2022)[J]. Med J Peking Union Med Coll Hosp, 2022,13(2):227－234. DOI：
10.12290/xhyxzz.2022-0089
.
[25]
Hausner SH , DiCara D , Marik J ,et al.
Use of a peptide derived from foot－and－mouth disease virus for the noninvasive imaging of human cancer: generation and evaluation of 4－[
18
F
]
fluorobenzoyl A20FMDV2 for
in vivo
imaging of integrin α
v
β
6
expression with positron emission tomography
[J]. Cancer Res, 2007,67(16):7833－7840. DOI：
10.1158/0008-5472.CAN-07-1026
.
[26]
Hausner SH , Bold RJ , Cheuy LY ,et al.
Preclinical development and first－in－human imaging of the integrin α
v
β
6
with [
18
F
]
α
v
β
6
－binding peptide in metastatic carcinoma
[J]. Clin Cancer Res, 2019,25(4):1206－1215. DOI：
10.1158/1078-0432.CCR-18-2665
.
[27]
Hausner SH , Bauer N , Davis RA ,et al.
The effects of an albumin binding moiety on the targeting and pharmacokinetics of an integrin α
v
β
6
－selective peptide labeled with aluminum [
18
F
]
fluoride
[J]. Mol Imaging Biol, 2020,22(6):1543－1552. DOI：
10.1007/s11307-020-01500-0
.
[28]
Ganguly T , Bauer N , Davis RA ,et al.
Evaluation of copper－64－labeled α
v
β
6
－targeting peptides: addition of an albumin binding moiety to improve pharmacokinetics
[J]. Mol Pharm, 2021,18(12):4437－4447. DOI：
10.1021/acs.molpharmaceut.1c00632
.
[29]
Davis RA , Hausner SH , Harris R ,et al.
A comparison of Evans blue and 4－(
p
－iodophenyl)butyryl albumin binding moieties on an integrin α
v
β
6
binding peptide
[J]. Pharmaceutics, 2022,14(4):745. DOI：
10.3390/pharmaceutics14040745
.
[30]
Ganguly T , Bauer N , Davis RA ,et al.
Preclinical evaluation of
68
Ga－ and
177
Lu－labeled integrin α
v
β
6
－targeting radiotheranostic peptides
[J]. J Nucl Med, 2023,64(4):639－644. DOI：
10.2967/jnumed.122.264749
.
[31]
Davis R , Foster C , Ganguly T ,et al.
First－in－human study of the theranostic pair [
68
Ga
]
Ga DOTA－5G and [
177
Lu
]
Lu DOTA－ABM－5G in pancreatic adenocarcinoma
[J]. J Nucl Med, 2023,64(supplement 1):P1300.
[32]
Kimura RH , Wang L , Shen B ,et al.
Evaluation of integrin α
v
β
6
cystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis
[J]. Nat Commun, 2019,10(1):4673. DOI：
10.1038/s41467-019-11863-w
.
[33]
Liu Z , Liu H , Ma T ,et al.
Integrin α
v
β
6
－targeted SPECT imaging for pancreatic cancer detection
[J]. J Nucl Med, 2014,55(6):989－994. DOI：
10.2967/jnumed.113.132969
.
[34]
Feng X , Wang Y , Lu D ,et al.
Clinical translation of a
68
Ga－labeled integrin α
v
β
6
－targeting cyclic radiotracer for PET imaging of pancreatic cancer
[J]. J Nucl Med, 2020,61(10):1461－1467. DOI：
10.2967/jnumed.119.237347
.
[35]
Quigley NG , Czech N , Sendt W ,et al.
PET/CT imaging of pancreatic carcinoma targeting the
"
cancer integrin
"
α
v
β
6
[J]. Eur J Nucl Med Mol Imaging, 2021,48(12):4107－4108. DOI：
10.1007/s00259-021-05443-8
.
[36]
Quigley NG , Steiger K , Hoberück S ,et al.
PET/CT imaging of head－and－neck and pancreatic cancer in humans by targeting the
"
Cancer Integrin
"
α
v
β
6
with Ga－68－Trivehexin
[J]. Eur J Nucl Med Mol Imaging, 2022,49(4):1136－1147. DOI：
10.1007/s00259-021-05559-x
.
[37]
Altmann A , Sauter M , Roesch S ,et al.
Identification of a novel ITGα
v
β
6
－binding peptide using protein separation and phage display
[J]. Clin Cancer Res, 2017,23(15):4170－4180. DOI：
10.1158/1078-0432.CCR-16-3217
.
[38]
Flechsig P , Lindner T , Loktev A ,et al.
PET/CT imaging of NSCLC with a α
v
β
6
integrin－targeting peptide
[J]. Mol Imaging Biol, 2019,21(5):973－983. DOI：
10.1007/s11307-018-1296-6
.
[39]
Roesch S , Lindner T , Sauter M ,et al.
Comparison of the RGD motif－containing α
v
β
6
integrin－binding peptides SFLAP3 and SFITGv6 for diagnostic application in HNSCC
[J]. J Nucl Med, 2018,59(11):1679－1685. DOI：
10.2967/jnumed.118.210013
.
[40]
Di Leva FS , Tomassi S , Di Maro S ,et al.
From a helix to a small cycle: metadynamics－inspired α
v
β
6
integrin selective ligands
[J]. Angew Chem Int Ed Engl, 2018,57(44):14645－14649. DOI：
10.1002/anie.201803250
.
[41]
Quigley NG , Tomassi S , Di Leva FS ,et al.
Click－chemistry (CuAAC) trimerization of an α
v
β
6
integrin targeting Ga－68－peptide: enhanced contrast for
in
－
vivo
PET imaging of human lung adenocarcinoma xenografts
[J]. Chembiochem, 2020,21(19):2836－2843. DOI：
10.1002/cbic.202000200
.
[42]
Kossatz S , Beer AJ , Notni J .
It′s time to shift the paradigm: translation and clinical application of non－α
v
β
3
integrin targeting radiopharmaceuticals
[J]. Cancers (Basel), 2021,13(23):5958. DOI：
10.3390/cancers13235958
.
[43]
Huang CW , Hsieh WC , Hsu ST ,et al.
The use of PET imaging for prognostic integrin α
2
β
1
phenotyping to detect non－small cell lung cancer and monitor drug resistance responses
[J]. Theranostics, 2017,7(16):4013－4028. DOI：
10.7150/thno.19304
.
[44]
Lu X , Wu M , Wang S ,et al.
Development and preliminary evaluation of an integrin α
2
β
1
－targeted PET probe as a supplement and alternative of PSMA imaging for prostate cancer
[J]. Bioorg Med Chem, 2022,54:116583. DOI：
10.1016/j.bmc.2021.116583
.
[45]
Huang CW , Li Z , Cai H ,et al.
Design, synthesis and validation of integrin α
2
β
1
－targeted probe for microPET imaging of prostate cancer
[J]. Eur J Nucl Med Mol Imaging, 2011,38(7):1313－1322. DOI：
10.1007/s00259-011-1752-x
.
[46]
Beaino W , Anderson CJ .
PET imaging of very late antigen－4 in melanoma: comparison of
68
Ga－ and
64
Cu－labeled NODAGA and CB－TE1A1P－LLP2A conjugates
[J]. J Nucl Med, 2014,55(11):1856－1863. DOI：
10.2967/jnumed.114.144881
.
[47]
Beaino W , Nedrow JR , Anderson CJ .
Evaluation of
68
Ga－ and
177
Lu－DOTA－PEG
4
－LLP2A for VLA－4－targeted PET imaging and treatment of metastatic melanoma
[J]. Mol Pharm, 2015,12(6):1929－1938. DOI：
10.1021/mp5006917
.
[48]
Hou J , Yan D , Liu Y ,et al.
The roles of integrin α
5
β
1
in human cancer
[J]. Onco Targets Ther, 2020,13:13329－13344. DOI：
10.2147/OTT.S273803
.
[49]
Notni J , Steiger K , Hoffmann F ,et al.
Complementary, selective PET imaging of integrin subtypes α
5
β
1
and α
v
β
3
using
68
Ga－Aquibeprin and
68
Ga－Avebetrin
[J]. J Nucl Med, 2016,57(3):460－466. DOI：
10.2967/jnumed.115.165720
.
[50]
Kapp TG , Di Leva FS , Notni J ,et al.
N－methylation of isoDGR peptides: discovery of a selective α
5
β
1
－integrin ligand as a potent tumor imaging agent
[J]. J Med Chem, 2018,61(6):2490－2499. DOI：
10.1021/acs.jmedchem.7b01752
.
[51]
Zhao H , Gao H , Zhai L ,et al.
99
Tc
m
－HisoDGR as a potential SPECT probe for orthotopic glioma detection via targeting of integrin α
5
β
1
[J]. Bioconjug Chem, 2016,27(5):1259－1266. DOI：
10.1021/acs.bioconjchem.6b00098
.
[52]
Gao H , Luo C , Yang G ,et al.
Improved
in vivo
targeting capability and pharmacokinetics of
99
Tc
m
－labeled isoDGR by dimerization and albumin－binding for glioma imaging
[J]. Bioconjug Chem, 2019,30(7):2038－2048. DOI：
10.1021/acs.bioconjchem.9b00323
.
[53]
Reichart F , Maltsev OV , Kapp TG ,et al.
Selective targeting of integrin α
v
β
8
by a highly active cyclic peptide
[J]. J Med Chem, 2019,62(4):2024－2037. DOI：
10.1021/acs.jmedchem.8b01588
.
[54]
Quigley NG , Steiger K , Richter F ,et al.
Tracking a TGF－β activator
in vivo:
sensitive PET imaging of α
v
β
8
－integrin with the Ga－68－labeled cyclic RGD octapeptide trimer Ga－68－Triveoctin
[J]. EJNMMI Res, 2020,10(1):133. DOI：
10.1186/s13550-020-00706-1
.
[55]
Wang T , Peng Y , Li R ,et al.
Preliminary study on SPECT/CT imaging of pancreatic cancer xenografts by targeting integrin α
5
in pancreatic stellate cells
[J]. J Cancer, 2021,12(6):1729－1733. DOI：
10.7150/jca.51190
.
[56]
Feng GK , Ye JC , Zhang WG ,et al.
Integrin α
6
targeted positron emission tomography imaging of hepatocellular carcinoma in mouse models
[J]. J Controlled Release, 2019,310:11－21. DOI：
10.1016/j.jconrel.2019.08.003
.
[57]
Gao S , Jia B , Feng G ,et al.
First－in－human pilot study of an integrin α
6
－targeted radiotracer for SPECT imaging of breast cancer
[J]. Signal Transduct Target Ther, 2020,5(1):147. DOI：
10.1038/s41392-020-00266-9
.
[58]
Luo Q , Yang G , Gao H ,et al. An integrin alpha 6－targeted radiotracer with improved receptor binding affinity and tumor uptake[J]. Bioconjug Chem, 2020,31(5):1510－1521. DOI：
10.1021/acs.bioconjchem.0c00170
.
[59]
Chen L , Fu H , He H ,et al.
automated synthesis and preclinical evaluation of optimized integrin α
6
－targeted positron emission tomography imaging of pancreatic cancer
[J]. Mol Pharm, 2023,20(8):4277－4284. DOI：
10.1021/acs.molpharmaceut.3c00321
.
[60]
Liu B , Zhang Z , Wang H ,et al.
Preclinical evaluation of a dual sstr2 and integrin α
v
β
3
－targeted heterodimer [
68
Ga
]
－NOTA－3PEG
4
－TATE－RGD
[J]. Bioorg Med Chem, 2019,27(21):115094. DOI：
10.1016/j.bmc.2019.115094
.
[61]
Zheng Y , Wang H , Tan H ,et al.
Evaluation of lung cancer and neuroendocrine neoplasm in a single scan by targeting both somatostatin receptor and integrin α
v
β
3
[J]. Clin Nucl Med, 2019,44(9):687－694. DOI：
10.1097/RLU.0000000000002680
.
[62]
Jiang Y , Liu Q , Wang G ,et al.
A prospective head－to－head co
mparison of
68
Ga－NOTA－3P－TATE－RGD and
68
Ga－DOTATATE in patients with gastroenteropancreatic neuroendocrine tumours
[J]. Eur J Nucl Med Mol Imaging, 2022,49(12):4218－4227. DOI：
10.1007/s00259-022-05852-3
.
[63]
蒋媛媛，郑玉民，朱朝晖.
68
Ga－NOTA－3P－TATE－RGD PET/CT在神经内分泌肿瘤中的应用
[J]. 中华核医学与分子影像杂志， 2023,43(11):649－654. DOI：
10.3760/cma.j.cn321828-20230905-00039
.
Jiang YY , Zheng YM , Zhu ZH .
Application of
68
Ga－NOTA－3P－TATE－RGD PET/CT in the evaluation of neuroendocrine neoplasms
[J]. Chin J Nucl Med Mol Imaging, 2023,43(11):649－654. DOI：
10.3760/cma.j.cn321828-20230905-00039
.
[64]
Hamson EJ , Keane FM , Tholen S ,et al. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy[J]. Proteomics Clin Appl, 2014,8(5－6):454－463. DOI：
10.1002/prca.201300095
.
[65]
Zang J , Wen X , Lin R ,et al.
Synthesis, preclinical evaluation and radiation dosimetry of a dual targeting PET tracer [
68
Ga
]
Ga－FAPI－RGD
[J]. Theranostics, 2022,12(16):7180－7190. DOI：
10.7150/thno.79144
.
[66]
Zang J , Lin R , Wen X ,et al.
A head－to－head comparison of
68
Ga－LNC1007 and 2－
18
F－FDG/
68
Ga－FAPI－02 PET/CT in patients with various cancers
[J]. Clin Nucl Med, 2023,48(10):861－868. DOI：
10.1097/RLU.0000000000004820
.
[67]
Wang R , Jakobsson V , Wang J ,et al.
Dual targeting PET tracer [
68
Ga
]
Ga－FAPI－RGD in patients with lung neoplasms: a pilot exploratory study
[J]. Theranostics, 2023,13(9):2979－2992. DOI：
10.7150/thno.86007
.
[68]
Zhao L , Wen X , Xu W ,et al.
Clinical Evaluation of
68
Ga－FAPI－RGD for imaging of fibroblast activation protein and integrin α
v
β
3
in various cancer types
[J]. J Nucl Med, 2023,64(8):1210－1217. DOI：
10.2967/jnumed.122.265383
.
[69]
Yan Q , Zhong J , Liu Y ,et al.
Synthesis and preclinical evaluation of a heterodimeric radioligand targeting fibroblast activation protein and integrin－α
v
β
3
[J]. Eur J Med Chem, 2023,251:115279. DOI：
10.1016/j.ejmech.2023.115279
.
[70]
Lv X , Song X , Long Y ,et al.
Preclinical evaluation of a dual－receptor targeted tracer [
68
Ga
]
Ga－HX01 in 10 different subcutaneous and orthotopic tumor models
[J]. Eur J Nucl Med Mol Imaging, 2023,51(1):54－67. DOI：
10.1007/s00259-023-06412-z
.
[71]
Zhang J , Niu G , Lang L ,et al.
Clinical translation of a dual integrin α
v
β
3
－ and gastrin－releasing peptide receptor－targeting PET radiotracer,
68
Ga－BBN－RGD
[J]. J Nucl Med, 2017,58(2):228－234. DOI：
10.2967/jnumed.116.177048
.
[72]
Zhang J , Mao F , Niu G ,et al.
68
Ga－BBN－RGD PET/CT for GRPR and integrin α
v
β
3
imaging in patients with breast cancer
[J]. Theranostics, 2018,8(4):1121－1130. DOI：
10.7150/thno.22601
.
[73]
Yao L , Li Y , Chen H ,et al.
Dual targeting of integrin α
v
β
3
and neuropilin－1 receptors improves micropositron emission tomography imaging of breast cancer
[J]. Mol Pharm, 2022,19(5):1458－1467. DOI：
10.1021/acs.molpharmaceut.1c01015
.
备注信息
A
霍力，Email:
nc.defhcabmupilouh
B
杨广杰：文献调研、论文撰写；霍力：研究指导、论文审阅与修改
C
所有作者声明无利益冲突
D
国家自然科学基金 (82071967)
中央高水平医院临床科研专项项目 (2022－PUMCH－D－001)
中国医学科学院医学与健康科技创新工程项目 (CIFMS－2021－I2M－1－025, CIFMS－2021－I2M－1－002, CIFMS－2021－I2M－1－003)
评论 （0条）
注册 登录
时间排序
- 时间排序
暂无评论，发表第一条评论抢沙发
分享
详细信息
表
访问与引文
阅读权限
参考文献
访问与引用
访问数据
0
0
全部时间 最近30天 最近6个月 最近12个月
MedAI助手（体验版）
文档即答
智问智答
机器翻译
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
生成快照
文献快照
文献快照
N/A
N/A
AI总结中
N/A
N/A
快照内容由人工智能生成，供您参考。
你好，我可以帮助您更好的了解本文，请向我提问您关注的问题。
0/50
很抱歉，当前对话已达到其限制。
使用"新建对话"按钮开启更多对话。
停止回答
0/2000
信息反馈
中文(简体)
英文
翻译
机器翻译功能由科大讯飞提供技术支持
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
你好！ 今天我能为您提供什么帮助？
0/30
of
很抱歉，当前对话已达到其限制。
使用"新建对话"按钮开启更多对话。
停止回答
扩写 缩写 改写 翻译
0/2000
信息反馈
历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号
小中大
翻译
润色
扩写
缩写
复制
引用
